Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Fr Ophtalmol ; 45(9): 1021-1023, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-36137867

RESUMO

We report the case of an 85-year-old patient who developed trifascicular block with syncope, triggered by preoperative eye drops for cataract surgery. This life-threatening situation reopens the debate over the necessity of having an anesthesiologist present during cataract surgery.


Assuntos
Extração de Catarata , Catarata , Humanos , Idoso de 80 Anos ou mais , Midriáticos/efeitos adversos , Soluções Oftálmicas/efeitos adversos , Extração de Catarata/efeitos adversos , Catarata/complicações , Catarata/diagnóstico , Síncope/diagnóstico , Síncope/etiologia
2.
Orphanet J Rare Dis ; 17(Suppl 1): 170, 2022 04 19.
Artigo em Inglês | MEDLINE | ID: mdl-35440056

RESUMO

Dunnigan syndrome, or Familial Partial Lipodystrophy type 2 (FPLD2; ORPHA 2348), is a rare autosomal dominant disorder due to pathogenic variants of the LMNA gene. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins), is to provide health professionals with a guide to optimal management and care of patients with FPLD2, based on a critical literature review and multidisciplinary expert consensus. The PNDS, written by members of the French National Reference Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), is available on the French Health Authority website (in French). Dunnigan syndrome is characterized by a partial atrophy of the subcutaneous adipose tissue and by an insulin resistance syndrome, associated with a risk of metabolic, cardiovascular and muscular complications. Its prevalence, assessed at 1/100.000 in Europe, is probably considerably underestimated. Thorough clinical examination is key to diagnosis. Biochemical testing frequently shows hyperinsulinemia, abnormal glucose tolerance and hypertriglyceridemia. Elevated hepatic transaminases (hepatic steatosis) and creatine phosphokinase, and hyperandrogenism in women, are common. Molecular analysis of the LMNA gene confirms diagnosis and allows for family investigations. Regular screening and multidisciplinary monitoring of the associated complications are necessary. Diabetes frequently develops from puberty onwards. Hypertriglyceridemia may lead to acute pancreatitis. Early atherosclerosis and cardiomyopathy should be monitored. In women, polycystic ovary syndrome is common. Overall, the management of patients with Dunnigan syndrome requires the collaboration of several health care providers. The attending physician, in conjunction with the national care network, will ensure that the patient receives optimal care through regular follow-up and screening. The various elements of this PNDS are described to provide such a support.


Assuntos
Hipertrigliceridemia , Resistência à Insulina , Lipodistrofia Parcial Familiar , Lipodistrofia , Pancreatite , Doença Aguda , Feminino , Humanos , Hipertrigliceridemia/complicações , Lipodistrofia Parcial Familiar/diagnóstico , Lipodistrofia Parcial Familiar/genética , Lipodistrofia Parcial Familiar/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA